公开(公告)号：US11702419B2

公开(公告)日：2023-07-18

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

CPC classification number: C07D487/04 ,  A61K9/2095 ,  A61K9/4833 ,  A61P25/00 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US11279713B2

公开(公告)日：2022-03-22

申请号：US16827316

申请日：2020-03-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni Kori ,  Toshihiro Imaeda ,  Shinji Nakamura ,  Masashi Toyofuku ,  Eiji Honda ,  Yasutomi Asano ,  Osamu Ujikawa ,  Michiyo Mochizuki

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US10654874B2

公开(公告)日：2020-05-19

申请号：US16256773

申请日：2019-01-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni Kori ,  Toshihiro Imaeda ,  Shinji Nakamura ,  Masashi Toyofuku ,  Eiji Honda

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20160159808A1

公开(公告)日：2016-06-09

申请号：US14907139

申请日：2014-07-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masanori Kawasaki ,  Satoshi Mikami ,  Shinji Nakamura ,  Nobuyuki Negoro ,  Shuhei Ikeda ,  Izumi Nomura ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Masaki Seto ,  Shigekazu Sasaki ,  Shogo Marui ,  Takahiko Taniguchi

IPC: C07D487/04 ,  C07D498/08 ,  C07D491/08 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D491/08 ,  C07D498/08

Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症，阿尔茨海默氏病等的预防或治疗药物。

公开(公告)号：US20150051197A1

公开(公告)日：2015-02-19

申请号：US14377106

申请日：2013-02-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masashi Toyofuki ,  Shinji Nakamura ,  Eiji Honda

IPC: C07D513/08 ,  C07D513/04

CPC classification number: C07D513/08 ,  C07D513/04 ,  C07D513/18

Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD) and the like. The compound represented by formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has an AMPA receptor function enhancing action, and is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 本发明提供具有AMPA受体功能增强作用的化合物，可用作抑郁，精神分裂症，阿尔茨海默病，注意力缺陷多动障碍（ADHD）等的预防或治疗药物。 由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐具有AMPA受体功能增强作用，并且可用作抑郁症，精神分裂症，阿尔茨海默病或注意力缺陷的预防或治疗药物 多动症（ADHD）等。

公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US09884875B2

公开(公告)日：2018-02-06

申请号：US15289650

申请日：2016-10-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni Kori ,  Toshihiro Imaeda ,  Shinji Nakamura ,  Masashi Toyofuku ,  Eiji Honda

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US09527841B2

公开(公告)日：2016-12-27

申请号：US14414020

申请日：2013-07-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji Nakamura ,  Satoshi Mikami ,  Kawasaki Masanori ,  Izumi Nomura ,  Tomoko Ashizawa ,  Takahiko Taniguchi

IPC: C07D241/38 ,  C07D471/04 ,  C07D235/16

CPC classification number: C07D471/04 ,  C07D235/16

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 本发明提供具有PDE2A选择性抑制作用的化合物，其可用作预防或治疗精神分裂症，阿尔茨海默氏病等。 本发明是由式（1）表示的化合物：其中每个符号如说明书中所述或其盐。

公开(公告)号：US08916551B2

公开(公告)日：2014-12-23

申请号：US13774707

申请日：2013-02-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni Kori ,  Toshihiro Imaeda ,  Shinji Nakamura ,  Masashi Toyofuku ,  Eiji Honda

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US09469637B2

公开(公告)日：2016-10-18

申请号：US14397066

申请日：2013-04-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Shinji Nakamura ,  Tomoko Ashizawa ,  Shigekazu Sasaki ,  Takahiko Taniguchi ,  Izumi Nomura ,  Masanori Kawasaki

IPC: C07D241/36 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.